Narrow Medium $39.90 Baxter $84.00 Wide Low $67 ..... stock look undervalued. Baxter BAX While competition is increasing for Advate, Baxter 's highly profitable hemophilia ..... Intangible assets--like Baxter 's strong brands, patent
Sept 29 (Reuters) - Baxter International Inc on Monday said it would form a research and development center in Cambridge, Massachusetts, for the biopharmaceutical business it expects to spin off as a separate company in mid-2015.
foot building at 650 East Kendall Street in Cambridge, MA is owned through a JV with Prudential Real Estate Investors. Baxter will be establishing a new global innovation and R&D center at the site for its biopharmaceuticals business. BioMed
AAT) treatment, Glassia , to Baxter International 's ( BAX -0.6% ) biopharmaceutical ..... payments for Glassia produced by Baxter is not expected to begin before 2018. Baxter is the exclusive distributor of
JERUSALEM, Sept 29 (Reuters) - Israeli drugmaker Kamada said on Monday it extended an agreement with Baxter International to supply a drug to treat emphysema through 2017.
Baxter International ( BAX -1.2% ) reports Q3 results on October 16. Its conference call will commence at 7:30 am CT. Consensus view is EPS of $1.30 on revenues of $4.2B. Post your comment!
company announced today a license agreement with Baxter (NYSE: BAX ) for MM-398, sending shares as much as 27 ..... Some key highlights of the license agreement with Baxter are as follows: Baxter agrees to develop and market MM-398 Complete
Merrimack Pharmaceuticals (NASDAQ: MACK ) is up 20% premarket on robust volume in response to its collaboration with Baxter . Post your comment!
NEW YORK, Sept 24 (Reuters) - Merrimack Pharmaceuticals shares were surging in premarket trade, up 24.5 percent to $8.95 after the company said it reached a deal to develop and market Merrimack's pancreatic cancer drug outside the U.S. with Baxter International .
Sept 24 (Reuters) - Drug developer Merrimack Pharmaceuticals Inc said it would partner with Baxter International Inc to develop and market its pancreatic cancer drug outside the United States, sending its shares up as much as 27 percent premarket.